Kalbe Farma Owned By Conglomerate Boenjamin Setiawan Gets IDR 1 Trillion Credit From BNI

President Director of PT Kalbe Farma Tbk Vidjongtius. (Photo: Doc. Kalbe Farma)

JAKARTA - PT Bank Negara Indonesia (Persero) Tbk has disbursed a financing facility worth Rp. 1 trillion to a pharmaceutical company owned by conglomerate Boenjamin Setiawan, PT Kalbe Farma Tbk (KLBF). The funds can later be used for business expansion, including additional capital expenditures or other Kalbe corporate actions.

BNI Corporate Banking Director Silvano Rumantir said the provision of this credit facility is a form of BNI's commitment as a national bank to support the development of priority sector businesses, including the health and pharmaceutical industries.

In the midst of the trend of recovery in economic performance, continued Silvano, banking industry players continue to open gaps for growth in the performance of the intermediation function to increase the leverage of economic recovery. As a state-owned bank that focuses on lending in the corporate segment, BNI is currently actively transforming and focusing on lending to top tier companies in Indonesia.

The health sector, including pharmaceuticals, is one of the leading sectors that is a priority for BNI in terms of business development and lending.

"Of course, apart from this credit cooperation, we will explore more potential collaborations with Kalbe Farma," Silvano said in a press release, quoted Thursday, June 30.

Meanwhile, President Director of PT Kalbe Farma Tbk Vidjongtius said this credit facility will directly support the company's business development from time to time in order to meet the health needs of the Indonesian people. The pharmaceutical industry is one of the industries that is quite resilient in dealing with the negative impacts of the COVID-19 pandemic.

This industry is also able to continue to grow its business in supporting the acceleration of national economic recovery as well as providing medicines, health products and nutrition to meet the needs of the community.

In 2021, Kalbe Farma's sales value will reach Rp. 26 trillion. In the first quarter of 2022, the Company's sales reached IDR 7 trillion or grew 16 percent compared to the first quarter of 2021 where sales reached IDR 6 trillion.